<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108886</url>
  </required_header>
  <id_info>
    <org_study_id>11-143</org_study_id>
    <nct_id>NCT02108886</nct_id>
  </id_info>
  <brief_title>Pilot Study Testing a New Strategy for Management of Spontaneous Preterm Birth</brief_title>
  <acronym>EAU2-Mtlk</acronym>
  <official_title>Pilot Study Testing a New Strategy for Management of Spontaneous Preterm Birth.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth is a major public health problem, and actual treatments are not very efficient.
      The purpose of this study is to test the efficiency of a combined use of Montelukast and
      Nifedipine to treat preterm labor. Investigators aim to reduce uterine contractions more
      efficiently than with the use of Nifedipine only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An inflammatory process is involved in 60% of preterm births. Moreover, investigators
      previously demonstrated that enzymes of lipoxygenase pathway are present in uterine smooth
      muscle, and that an additive tocolytic effect can be obtained from the combined use of
      Montelukast and Nifedipine.

      Methods:

      This is a double-blinded randomized controlled assay performed at the CHUS on two groups of
      50 women. Women will be selected when admitted for preterm labor with a gestational age
      between 26 and 34 weeks.

      The first group will receive Nifedipine for 48 hours, as described by the standard protocol
      at the CHUS, in addition to 10 mg of Montelukast per day, until delivery or 35 weeks of
      pregnancy.

      The second group will receive Nifedipine for 48 hours, as described by the standard protocol
      at the CHUS, in addition to a placebo per day, until delivery or 35 weeks of pregnancy.

      Cervical secretions and urine will be sample at the admission, after one week and every two
      weeks during treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time between beginning of treatment and delivery</measure>
    <time_frame>until delivery (max 17 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>preterm birth</measure>
    <time_frame>until delivery (max 13 weeks)</time_frame>
    <description>birth before 37 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chorio decidual infection</measure>
    <time_frame>between inclusion and delivery (max 17 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.</description>
    <arm_group_label>Montelukast</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>empty capsule filled with sugar</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine and vaginal secretions sampling</intervention_name>
    <description>Urine and vaginal secretions sampling, once a week in both groups</description>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with 24-34 weeks of pregnancy

          -  indication for tocolysis

        Exclusion Criteria:

          -  preterm labor before 26 or after 34 weeks of pregnancy

          -  minor patients

          -  patients with other obstetrical pathology

          -  twin pregnancies

          -  fetal distress

          -  severe congenital fetal malformation

          -  anti-phospholipid syndrome

          -  lupus

          -  gestational diabetes

          -  nephropathy

          -  congenital heart disease

          -  obvious causes of infection associated with prematurity

          -  patients with viral infections (HIV, hepatitis)

          -  patients already treated with Montelukast
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Charles Pasquier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Jean-Charles Pasquier, MD, PhD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>preterm labor</keyword>
  <keyword>montelukast</keyword>
  <keyword>uterine contractions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

